Postoperative pain relief in patients with nutritional deficiency in abdominal oncosurgery: the potential of the innovative Russian analgesic Tafalgin®

Introduction. A fairly large number of cancer patients with surgical pathology enter a hospital with nutritional insufficiency of varying degrees. According to the international screening study Nutrition Day, weight loss is associated with a higher risk of inpatient death within 30 days in patients undergoing surgery as compared with patients who were not treated surgically. pain syndrome in the postoperative period has a negative effect on all vital systems of the body, increases the wound healing period and creates a risk of adverse hemodynamic events, thromboembolic complications and chronic pain syndrome. Enhanced sympathetic stimulation inhibits peristalsis and enhances the smooth muscles tone of the intestine, which is fraught with the development of postoperative intestinal paresis. Opioid-associated adverse events such as respiratory depression, gastrointestinal disorders (nausea, vomiting, constipation), sleep, endocrinopathies, cognitive impairment, high risk of addiction and drug dependence impair the quality of care provided

Aim. To compare the effectiveness and safety of the innovative Russian analgesic Tafalgin® and morphine in cancer patients with nutritional insufficiency in the early postoperative period.

Materials and methods. The open-label randomized controlled trial included 80 patients who underwent abdominal surgery. patients received multimodal analgesia with either tafalgina or morphine.

Results. According to the data obtained during the study, tafalgin provides analgesia comparable to morphine, while contributing to earlier mobilization, reducing the length of hospital stay, reducing the incidence of postoperative complications, hypoxemia, nausea and vomiting. The drug was also associated with lower severity of sedation and daytime sleepiness.

Conclusion. Tafalgin has demonstrated high analgesic potential and a better safety profile as compared to morphine allowing its use in multimodal analgesia in cancer patients with nutritional insufficiency after abdominal surgery.

1. Gan T.J. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res 2017;10:2287–98. DOI: 10.2147/JPR.S144066

2. Xu R., Chen X.D., Ding Z. Perioperative nutrition management for gastric cancer. Nutrition 2022;93:111492. DOI: 10.1016/j.nut.2021.111492

3. GlobalSurg Collaborative and NIHR Global Health Unit on Global Surgery. Impact of malnutrition on early outcomes after cancer surgery: an international, multicentre, prospective cohort study. Lancet Glob Health 2023;11(3):e341–9. DOI: 10.1016/S2214-109X(22)00550-2

4. Muscaritoli M., Arends J., Bachmann P. et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr 202;40(5): 2898–913. DOI: 10.1016/j.clnu.2021.02.005

5. Kubota T., Shoda K., Konishi H. et al. Nutrition update in gastric cancer surgery. Ann Gastroenterol Surg 2020;4(4):360–8. DOI: 10.1002/ags3.12351

6. Cederholm T., Jensen G.L., Correia M.I.T.D. et al. GLIM criteria for the diagnosis of malnutrition – a consensus report from the global clinical nutrition community. Clin Nutr 2019;38(1):1–9. DOI: 10.1016/j.clnu.2018.08.002

7. Kianian S., Bansal J., Lee C. et al. Perioperative multimodal analgesia: a review of efficacy and safety of the treatment options. APS 2024;2(9). DOI: 10.1007/s44254-023-00043-1

8. Ramirez M.F., Strang A., Roland G. et al. Perioperative pain management and cancer outcomes: a narrative review. J Pain Res 2023;6:4181–9. DOI: 10.2147/JPR.S432444

9. National Cancer Institute. Cancer Pain (PDQ®) – Health Professional Version [Electronic resource]. Available at: https://www.cancer.gov/about-cancer/treatment/side-effects/pain/painhp-pdq

10. Kosorukov V.S., Abuzarova G.R., Zakharochkina E.R. et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholi golovy i shei = Head and Neck Tumors 2022;12(2):89–107. (In Russ.). DOI: 10.17650/2222-1468-2022-12-2-89-107